Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.47 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.47 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.47 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.47 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.47 |
| ▸ | NT5E | P21589 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 3/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.44 |
| ▸ | CDC25B | P30305 | 6/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.44 |
| ▸ | TACR2 | P21452 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16229071 | 1.00 | HTR1A (0.49) | HTR1ASSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL13164470 | 1.00 | HTR1A (0.49) | HTR1ASSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL21013401 | 1.00 | HTR1A (0.49) | HTR1ASSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL1033003 | 1.00 | HTR1A (0.49) | HTR1ASSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL16632218 | 1.00 | HTR1A (0.49) | HTR1ASSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL16632221 | 1.00 | HTR1A (0.49) | HTR1ASSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL8733842 | 1.00 | HTR1A (0.49) | HTR1ASSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL24119107 | 0.91 | BCHE (0.50) | HTR1ASSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL14001401 | 0.90 | HTR1A (0.46) | HTR1ASSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL12612549 | 0.90 | HTR1A (0.46) | HTR1ASSTR1SSTR2SSTR4SSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3052134-B1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME (US) | 2021-05-05 | — | — | EP | disclosed |
| CN-105792852-B | Glucose-responsive insulin conjugates | 默沙东公司 | 2019-12-10 | — | — | CN | disclosed |
| US-20180110863-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2018-04-26 | — | — | US | disclosed |
| EP-3280450-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | Merck Sharp & Dohme Corp. (US) | 2018-02-14 | — | — | EP | disclosed |
| US-9889205-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME CORP. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9884125-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20160303244-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2016-10-20 | — | — | US | disclosed |
| WO-2016164288-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2016-10-13 | — | — | WO | disclosed |
| US-20160251407-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2016-09-01 | — | — | US | disclosed |
| US-9427475-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME CORP. (US) | 2016-08-30 | — | — | US | disclosed |
| CN-105792852-A | Glucose-responsive insulin conjugates | 默沙东公司 | 2016-07-20 | — | — | CN | disclosed |
| US-20150105317-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME LLC | 2015-04-16 | — | — | US | disclosed |
| EP-2276773-A2 | COMPOUNDS WITH GLYCIDIC STRUCTURE ACTIVE IN THE THERAPY OF SYSTEMIC AND LOCAL INFLAMMATION | La Ferla, Barbara (IT) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009135673-A2 | COMPOUNDS WITH GLYCIDIC STRUCTURE ACTIVE IN THE THERAPY OF SYSTEMIC | LA FERLA BARBARA (IT) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180110863-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | HTR1A 3230/4885SSTR1 70/4885SSTR2 120/4885 |
| US-20150105317-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | HTR1A 2798/4885SSTR1 69/4885SSTR2 123/4885 |
| US-20160251407-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | HTR1A 3137/4885SSTR1 70/4885SSTR2 130/4885 |
| US-20160303244-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | HTR1A 2798/4885SSTR1 69/4885SSTR2 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.